IMPOWER130
Regimen
- Experimental
- atezo + carbo + nab-paclitaxel
- Control
- carbo + nab-paclitaxel
Population
1L non-sq NSCLC, EGFR/ALK-WT ITT
Key finding
mOS 18.6 vs 13.9 mo, HR 0.79 (0.64-0.98); 1L non-sq IO-chemo option
Source: PMID 31122901
Timeline
- Enrollment start: 2015-04-16 📎
Guideline citations
- NCCN NSCLC Version 5.2026 (p.113)
- CSCO NSCLC 2025 ⚠️ OCR source